Organizations aim to advance precision oncology and biomarker-driven research.
Caris Life Sciences, an artificial intelligence (AI) TechBio company, announced that Sarah Cannon Research Institute (SCRI), an oncology research organization, has officially joined the Caris Precision Oncology Alliance (POA). According to Caris, the POA is a network of cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
"SCRI and Caris share a commitment to advancing therapies and expanding access to molecular diagnostic approaches for patients in the community," said Andrew McKenzie, PhD, VP, personalized medicine, SCRI; scientific director, Genospace. "We are pleased to join the Caris Precision Oncology Alliance and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer."
Reference: The Caris Precision Oncology Alliance Welcomes Sarah Cannon Research Institute. PR Newswire. October 26, 2023. Accessed October 27, 2023. https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-sarah-cannon-research-institute-301968199.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.